COST OF ILLNESS PASIEN KANKER PARU-PARU RAWAT INAP DI RUMAH SAKIT DI BANDUNG
Abstract
Penyakit kanker merupakan penyakit katastropik yang membutuhkan biaya yang yang besar. Cost of illness merupakan faktor penting dalam pengambilan keputusan karena menjadi suatu metode untuk menilai beban ekonomi dari penyakit. Penelitian ini bertujuan untuk melakukan analisis Cost Of Illness pada pasien rawat inap yang mengidap penyakit kanker paru-paru peserta JKN . Penelitian ini merupakan penelitian observational dengan rancangan deskriptif cross sectional menggunakan hasil studi pembiayaan yang dilakukan salah satu RSUD di Bandung. Data yang diambil merupakan data rekam medis dan biaya medis pasien ddpada periode Januari- Juni 2023. Didapatkan sebanyak 21 populasi dengan 27 episode perawatan yang sesuai kriteria inklusi yang menunjukkan total biaya rill berdasarkan perspektif rumah sakit pada pasien Tumor Paru dengan kode INA-CBG’s (J-4-14) sebesar Rp. 107.865.061 dan pasien dengan total biaya pada penyakit Prosedur Sisten Pernafasan Sangat Kompleks (J-1-10) sebesar Rp. 34.627.221. Sedangkan Perbandingan selisih dari tarif INA-CBG’s dengan tarif rill pada pasien kanker didapatkan hasil selisih total Rp. 143.633.469. Kesimpulan dari penelitian ini terjadi selisih positif dimana biaya kesehatan dengan perspektif rumah sakit lebih rendah daripada nilai INA CBG’s
References
Agboado, G., Peters, J., & Donkin, L. (2012). Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: A cross-sectional study. BMJ Open, 2(5). https://doi.org/10.1136/bmjopen-2012-000869
Aisyah, N., Aryzki, S., Wahyuni, A., Andayani, T. M., & Puspandari, D. A. (2019). Factors affecting the real cost Of chemotherapy for patients with breast cancer of JKN participants in RSUD Ulin Banjarmasin. Journal of Current Pharmaceutical Sciences, 2(2), 2598–2095.
Aisyah, N., & Dina, S. P. (2020). Cost of Illness Pada Pasien Penyakit Kanker Payudara Di Rsud Ulin Banjarmasin. Jurnal Ilmiah Ibnu Sina (JIIS) Ilmu Farmasi Dan Kesehatan, 5(2), 407–415. https://doi.org/10.36387/jiis.v5i2.573
Aisyah, N., Saputra, Y., & Mardiana, M. (2019). Komparasi BIaya Rill dengan Tarif Tarif INA-CBG’s Pada Pasien Rawat Inap Kemoterapi Kanker Parus di RSUD Ulin Banjarmasin. Jurnal Insan Farmasi Indonesia, 2(2), 212–221. https://doi.org/10.36387/jifi.v2i2.401
Ambarriani, A. S. (2014). Hospital financial performance in the Indonesian national health insurance era. Integrative Business and Economics Research, 4, 121–133.
Andarini, S., Syahruddin, E., Aditya, N., Zaini, J., Kurniawan, F. D., Ermayanti, S., Soeroso, N. N., Munir, S. M., Infianto, A., Rima, A., Setyawan, U. A., Wulandari, L., Haryati, H., Jasminarti, I. A., & Santoso, A. (2023). Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia. Jurnal Respirologi Indonesia, 43(2), 144–150. https://doi.org/10.36497/jri.v43i2.455
Andrade, P., Sacristan, J. A., & Dilla, T. (2017). Health Economics & Outcome Research : The Economic Burden of Cancer in Spain : A Literature Review. Health Economics & Outcome Research: Open Access, 3(1), 1–8. https://doi.org/10.4172/2471-268X/1000125
Andriani, Y., Kristina, S. A., & Wiedyaningsih, C. (2021). Estimasi Biaya Pengobatan Langsung Penyakit Kanker di Indonesia: Estimasi Direct Medical Cost (DMC) Estimation of Direct Medical Cost of Cancer in Indonesia: Estimasi Direct Medical Cost (DMC). Majalah Farmaseutik, 17(3), 251–255. https://doi.org/10.22146/farmaseutik.v1i1.49823
Budiarto, W., & Sugiharto, M. (2013). Biaya Klaim INA CBGs dan Biaya Riil Penyakit Katastropik Rawat Inap Peserta Jamkesmas di Rumah Sakit Studi di 10 Rumah Sakit Milik Kementrian Kesehatan Januari-Maret 2012. Buletin Penelitian Sistem Kesehatan, Volume 16(1), 58–65.
Cook, K., Dranove, D., & Sfekas, A. (2010). Does major illness cause financial catastrophe? Health Services Research, 45(2), 418–436. https://doi.org/10.1111/j.1475-6773.2009.01049.x
El Harch, I., Guendaoui, S., Charkaoui, M., Benmaamar, S., Omari, M., EL Youbi, M., Belakhhel, L., Abouselham, L., Hachri, H., El Menchay, I., El Fakir, S., Berraho, M., Benchekroun, N., & Tachfouti, N. (2023). Economic burden of lung cancer in Morocco: A cost of illness study. Journal of Cancer Policy, 37(June), 100428. https://doi.org/10.1016/j.jcpo.2023.100428
Ellis, P. M., & Vandermeer, R. (2011). Delays in the diagnosis of lung cancer. Journal of Thoracic Disease, 3(3), 183–188. https://doi.org/10.3978/j.issn.2072-1439.2011.01.01
Febriani, A., & Furqon, A. (2020). Metastasis Kanker Paru. Jurnal Respirasi, 4(3), 94. https://doi.org/10.20473/jr.v4-i.3.2018.94-101
Gondhowiardjo, S., Christina, N., Ganapati, N. P. D., Hawariy, S., Radityamurti, F., Jayalie, V. F., Octavianus, S., Prawira Putra, A., Sekarutami, S. M., Prajogi, G. B., Giselvania, A., Adham, M., Hamid, A. R. A. H., Widyastuti, E., Prabowo, Y., Aninditha, T., Purwoto, G., Aman, R. A., Siregar, T. P., … Agianda, F. (2021). Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. JCO Global Oncology, 7, 190–203. https://doi.org/10.1200/go.20.00155
Heniwati, & Thabrany, H. (2017). Comparison of catastrophic disease claims for National Health Insurance participants in DKI Jakarta and East Nusa Tenggara Provinces in 2014. Jurnal Ekonomi Kesehatan Indonesia, 1(2), 18–27. https://doi.org/10.7454/eki.v1i2.1771
Kemenkes RI. (2023). Peraturan Menteri Kesehatan Republik Indonesia No. 3 Tahun 2023 Tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Program Jaminan Kesehatan. Menteri Kesehatan RI, 1–721.
Kula, J. I. (2013). Hospitalization fee determination method on BLU RSUP Prof. Dr. R. D. Kandou Manado. Jurnal EMBA, Vol 1 No 3(3), 793–803.
Lubis, I. K., & Susilawati. (2017). Analisis Length Of Stay ( Los ) Berdasarkan Faktor Prediktor Pada Pasien DM Tipe II di RS PKU Muhammadiyah Yogyakarta. Jurnal Kesehatan Vokasional, 2(2), 161–166.
Manawan, F., Widodo, G., & Andayani, T. M. (2019). Cost of illness in breast cancer patients at The National General Hospital Prof. Dr. R.D Kandou Manado. Jurnal Farmasi Medica/Pharmacy Medical Journal (PMJ), 2(2), 86. https://doi.org/10.35799/pmj.2.2.2019.26532
Muslimah., Tri M.A., Rizaldy, P., Dwi, E. (2017). Comparison of real costs againts the price of INA-CBG’s Ischemic store in Bethesda hospital Yogyakarta. Jurnal Manajemen Dan Pelayanan Farmasi, 7(2), 105–114.
Omeati, R. (2015). Review Penelitian Kanker Paru di Indonesia Review of Lung Cancer Research in Indonesia. Persada Husada Indonesia, 1–9.
Politiek, K., Oosterhaven, J. A. F., Vermeulen, K. M., & Schuttelaar, M. L. A. (2016). Systematic review of cost-of-illness studies in hand eczema. Contact Dermatitis, 75(2), 67–76. https://doi.org/10.1111/cod.12590
Puspandari, D. A., Mukti, A. G., Kusnanto, H., Kebijakan, P., & Asuransi, M. (2015). Determinant factors of drug cost for breast cancer patient in Indonesia. Jurnal Kebijakan Kesehatan Indonesia : JKKI, 04(03), 104–108.
Rami-Porta, R., Call, S., Dooms, C., Obiols, C., Sánchez, M., Travis, W. D., & Vollmer, I. (2018). Lung cancer staging: A concise update. European Respiratory Journal, 51(5), 1–17. https://doi.org/10.1183/13993003.00190-2018
Salim, M. F., Lubis, I. K., & Sugeng, S. (2019). Differences in length of stay (LOS) in diabetes mellitus patients based on complications at Dr. Sardjito Yogyakarta. Jurnal Manajemen Informasi Kesehatan Indonesia, 7(1), 17. https://doi.org/10.33560/jmiki.v7i1.216
Satibi, S., Andayani, T. M., Endarti, D., Suwantara, I. P. T., Wintariani, N. P., & Agustini, N. P. D. (2019). Comparison of real cost versus The Indonesian Case Base Groups (INA-CBGs) tariff rates among patients of high- incidence cancers under the national health insurance scheme. Asian Pacific Journal of Cancer Prevention, 20(1), 117–122. https://doi.org/10.31557/APJCP.2019.20.1.117
Satibi, S., Daulay, E. H., Oviani, G. A., Erlianti, K., Fudholi, A., & Puspandari, D. A. (2018). Performance analysis of pharmacist and influencing factors in the era of National Health Insurance at Puskesmas. Journal of Management and Pharmacy Practice, 8(1), 32. https://doi.org/10.22146/jmpf.34441
Seung, S. J., Hurry, M., Hassan, S., Walton, R. N., & Evans, W. K. (2019). Cost-of-illness study for non-small-cell lung cancer using real-world data. Current Oncology, 26(2), 102–107. https://doi.org/10.3747/co.26.4555
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Taheri, P. A., Butz, D. A., & Greenfield, L. J. (2000). Length of stay has minimal impact on the cost of hospital admission. Journal of the American College of Surgeons, 191(2), 123–130. https://doi.org/10.1016/S1072-7515(00)00352-5
Tarigan, S. P., Soeroso, N. N., Tumanggor, C. A. K., Gani, S., & Pradana, A. (2019). Clinical profile of male patients with non-small cell lung cancer in Adam Malik General Hospital, Medan, Indonesia. Open Access Macedonian Journal of Medical Sciences, 7(16), 2612–2614. https://doi.org/10.3889/oamjms.2019.404
Wood, D. E., Kazerooni, E. A., & Baum, S. L. (2018). Lung Cancer Screening, Version 3.2018. NCCN Clinical Practice Guidelines in Oncology. Journal of National Comprehensive Cancer Network, 16(4), 412–441. https://doi.org/10.6004/jnccn.2018.0020.Lung
Yershova, K., Yuan, J.-M., Wang, R., Valentin, L., Watson, C., Gao, Y.-T., Hect, S. S., & Sthepanov, I. (2016). Tobacco-specific N-nitrosamines and polycyclic aromatic hydrocarbons in cigarettes smoked by the participants of the Shanghai Cohort Study. Int J Cancer, 139(6), 1–19. https://doi.org/10.1002/ijc.30178.
Yousefi, M., Jalilian, H., Heydari, S., Seyednejad, F., & Mir, N. (2023). Cost of Lung Cancer: A Systematic Review. Value in Health Regional Issues, 33, 17–26. https://doi.org/10.1016/j.vhri.2022.07.007
Yousefi, N., Polroudi Moghaddam, M., Afsharmanesh, G., & Peiravian, F. (2020). Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment. International Journal of Health Planning and Management, 35(6), 1503–1511. https://doi.org/10.1002/hpm.3028
Yuliastuti, F., Andayani, T. M., Endarti, D., & Kristina, S. A. (2023). Breast, cervical, and lung cancer: A comparison of real healthcare costs and INA-CBGs rates in the era of national health insurance. Pharmacy Practice, 21(1), 1–7. https://doi.org/10.18549/PharmPract.2023.1.2768
Aisyah, N., Aryzki, S., Wahyuni, A., Andayani, T. M., & Puspandari, D. A. (2019). Factors affecting the real cost Of chemotherapy for patients with breast cancer of JKN participants in RSUD Ulin Banjarmasin. Journal of Current Pharmaceutical Sciences, 2(2), 2598–2095.
Aisyah, N., & Dina, S. P. (2020). Cost of Illness Pada Pasien Penyakit Kanker Payudara Di Rsud Ulin Banjarmasin. Jurnal Ilmiah Ibnu Sina (JIIS) Ilmu Farmasi Dan Kesehatan, 5(2), 407–415. https://doi.org/10.36387/jiis.v5i2.573
Aisyah, N., Saputra, Y., & Mardiana, M. (2019). Komparasi BIaya Rill dengan Tarif Tarif INA-CBG’s Pada Pasien Rawat Inap Kemoterapi Kanker Parus di RSUD Ulin Banjarmasin. Jurnal Insan Farmasi Indonesia, 2(2), 212–221. https://doi.org/10.36387/jifi.v2i2.401
Ambarriani, A. S. (2014). Hospital financial performance in the Indonesian national health insurance era. Integrative Business and Economics Research, 4, 121–133.
Andarini, S., Syahruddin, E., Aditya, N., Zaini, J., Kurniawan, F. D., Ermayanti, S., Soeroso, N. N., Munir, S. M., Infianto, A., Rima, A., Setyawan, U. A., Wulandari, L., Haryati, H., Jasminarti, I. A., & Santoso, A. (2023). Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia. Jurnal Respirologi Indonesia, 43(2), 144–150. https://doi.org/10.36497/jri.v43i2.455
Andrade, P., Sacristan, J. A., & Dilla, T. (2017). Health Economics & Outcome Research : The Economic Burden of Cancer in Spain : A Literature Review. Health Economics & Outcome Research: Open Access, 3(1), 1–8. https://doi.org/10.4172/2471-268X/1000125
Andriani, Y., Kristina, S. A., & Wiedyaningsih, C. (2021). Estimasi Biaya Pengobatan Langsung Penyakit Kanker di Indonesia: Estimasi Direct Medical Cost (DMC) Estimation of Direct Medical Cost of Cancer in Indonesia: Estimasi Direct Medical Cost (DMC). Majalah Farmaseutik, 17(3), 251–255. https://doi.org/10.22146/farmaseutik.v1i1.49823
Budiarto, W., & Sugiharto, M. (2013). Biaya Klaim INA CBGs dan Biaya Riil Penyakit Katastropik Rawat Inap Peserta Jamkesmas di Rumah Sakit Studi di 10 Rumah Sakit Milik Kementrian Kesehatan Januari-Maret 2012. Buletin Penelitian Sistem Kesehatan, Volume 16(1), 58–65.
Cook, K., Dranove, D., & Sfekas, A. (2010). Does major illness cause financial catastrophe? Health Services Research, 45(2), 418–436. https://doi.org/10.1111/j.1475-6773.2009.01049.x
El Harch, I., Guendaoui, S., Charkaoui, M., Benmaamar, S., Omari, M., EL Youbi, M., Belakhhel, L., Abouselham, L., Hachri, H., El Menchay, I., El Fakir, S., Berraho, M., Benchekroun, N., & Tachfouti, N. (2023). Economic burden of lung cancer in Morocco: A cost of illness study. Journal of Cancer Policy, 37(June), 100428. https://doi.org/10.1016/j.jcpo.2023.100428
Ellis, P. M., & Vandermeer, R. (2011). Delays in the diagnosis of lung cancer. Journal of Thoracic Disease, 3(3), 183–188. https://doi.org/10.3978/j.issn.2072-1439.2011.01.01
Febriani, A., & Furqon, A. (2020). Metastasis Kanker Paru. Jurnal Respirasi, 4(3), 94. https://doi.org/10.20473/jr.v4-i.3.2018.94-101
Gondhowiardjo, S., Christina, N., Ganapati, N. P. D., Hawariy, S., Radityamurti, F., Jayalie, V. F., Octavianus, S., Prawira Putra, A., Sekarutami, S. M., Prajogi, G. B., Giselvania, A., Adham, M., Hamid, A. R. A. H., Widyastuti, E., Prabowo, Y., Aninditha, T., Purwoto, G., Aman, R. A., Siregar, T. P., … Agianda, F. (2021). Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. JCO Global Oncology, 7, 190–203. https://doi.org/10.1200/go.20.00155
Heniwati, & Thabrany, H. (2017). Comparison of catastrophic disease claims for National Health Insurance participants in DKI Jakarta and East Nusa Tenggara Provinces in 2014. Jurnal Ekonomi Kesehatan Indonesia, 1(2), 18–27. https://doi.org/10.7454/eki.v1i2.1771
Kemenkes RI. (2023). Peraturan Menteri Kesehatan Republik Indonesia No. 3 Tahun 2023 Tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Program Jaminan Kesehatan. Menteri Kesehatan RI, 1–721.
Kula, J. I. (2013). Hospitalization fee determination method on BLU RSUP Prof. Dr. R. D. Kandou Manado. Jurnal EMBA, Vol 1 No 3(3), 793–803.
Lubis, I. K., & Susilawati. (2017). Analisis Length Of Stay ( Los ) Berdasarkan Faktor Prediktor Pada Pasien DM Tipe II di RS PKU Muhammadiyah Yogyakarta. Jurnal Kesehatan Vokasional, 2(2), 161–166.
Manawan, F., Widodo, G., & Andayani, T. M. (2019). Cost of illness in breast cancer patients at The National General Hospital Prof. Dr. R.D Kandou Manado. Jurnal Farmasi Medica/Pharmacy Medical Journal (PMJ), 2(2), 86. https://doi.org/10.35799/pmj.2.2.2019.26532
Muslimah., Tri M.A., Rizaldy, P., Dwi, E. (2017). Comparison of real costs againts the price of INA-CBG’s Ischemic store in Bethesda hospital Yogyakarta. Jurnal Manajemen Dan Pelayanan Farmasi, 7(2), 105–114.
Omeati, R. (2015). Review Penelitian Kanker Paru di Indonesia Review of Lung Cancer Research in Indonesia. Persada Husada Indonesia, 1–9.
Politiek, K., Oosterhaven, J. A. F., Vermeulen, K. M., & Schuttelaar, M. L. A. (2016). Systematic review of cost-of-illness studies in hand eczema. Contact Dermatitis, 75(2), 67–76. https://doi.org/10.1111/cod.12590
Puspandari, D. A., Mukti, A. G., Kusnanto, H., Kebijakan, P., & Asuransi, M. (2015). Determinant factors of drug cost for breast cancer patient in Indonesia. Jurnal Kebijakan Kesehatan Indonesia : JKKI, 04(03), 104–108.
Rami-Porta, R., Call, S., Dooms, C., Obiols, C., Sánchez, M., Travis, W. D., & Vollmer, I. (2018). Lung cancer staging: A concise update. European Respiratory Journal, 51(5), 1–17. https://doi.org/10.1183/13993003.00190-2018
Salim, M. F., Lubis, I. K., & Sugeng, S. (2019). Differences in length of stay (LOS) in diabetes mellitus patients based on complications at Dr. Sardjito Yogyakarta. Jurnal Manajemen Informasi Kesehatan Indonesia, 7(1), 17. https://doi.org/10.33560/jmiki.v7i1.216
Satibi, S., Andayani, T. M., Endarti, D., Suwantara, I. P. T., Wintariani, N. P., & Agustini, N. P. D. (2019). Comparison of real cost versus The Indonesian Case Base Groups (INA-CBGs) tariff rates among patients of high- incidence cancers under the national health insurance scheme. Asian Pacific Journal of Cancer Prevention, 20(1), 117–122. https://doi.org/10.31557/APJCP.2019.20.1.117
Satibi, S., Daulay, E. H., Oviani, G. A., Erlianti, K., Fudholi, A., & Puspandari, D. A. (2018). Performance analysis of pharmacist and influencing factors in the era of National Health Insurance at Puskesmas. Journal of Management and Pharmacy Practice, 8(1), 32. https://doi.org/10.22146/jmpf.34441
Seung, S. J., Hurry, M., Hassan, S., Walton, R. N., & Evans, W. K. (2019). Cost-of-illness study for non-small-cell lung cancer using real-world data. Current Oncology, 26(2), 102–107. https://doi.org/10.3747/co.26.4555
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Taheri, P. A., Butz, D. A., & Greenfield, L. J. (2000). Length of stay has minimal impact on the cost of hospital admission. Journal of the American College of Surgeons, 191(2), 123–130. https://doi.org/10.1016/S1072-7515(00)00352-5
Tarigan, S. P., Soeroso, N. N., Tumanggor, C. A. K., Gani, S., & Pradana, A. (2019). Clinical profile of male patients with non-small cell lung cancer in Adam Malik General Hospital, Medan, Indonesia. Open Access Macedonian Journal of Medical Sciences, 7(16), 2612–2614. https://doi.org/10.3889/oamjms.2019.404
Wood, D. E., Kazerooni, E. A., & Baum, S. L. (2018). Lung Cancer Screening, Version 3.2018. NCCN Clinical Practice Guidelines in Oncology. Journal of National Comprehensive Cancer Network, 16(4), 412–441. https://doi.org/10.6004/jnccn.2018.0020.Lung
Yershova, K., Yuan, J.-M., Wang, R., Valentin, L., Watson, C., Gao, Y.-T., Hect, S. S., & Sthepanov, I. (2016). Tobacco-specific N-nitrosamines and polycyclic aromatic hydrocarbons in cigarettes smoked by the participants of the Shanghai Cohort Study. Int J Cancer, 139(6), 1–19. https://doi.org/10.1002/ijc.30178.
Yousefi, M., Jalilian, H., Heydari, S., Seyednejad, F., & Mir, N. (2023). Cost of Lung Cancer: A Systematic Review. Value in Health Regional Issues, 33, 17–26. https://doi.org/10.1016/j.vhri.2022.07.007
Yousefi, N., Polroudi Moghaddam, M., Afsharmanesh, G., & Peiravian, F. (2020). Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment. International Journal of Health Planning and Management, 35(6), 1503–1511. https://doi.org/10.1002/hpm.3028
Yuliastuti, F., Andayani, T. M., Endarti, D., & Kristina, S. A. (2023). Breast, cervical, and lung cancer: A comparison of real healthcare costs and INA-CBGs rates in the era of national health insurance. Pharmacy Practice, 21(1), 1–7. https://doi.org/10.18549/PharmPract.2023.1.2768
Published
2024-04-30
How to Cite
SKARAYADI, Oskar et al.
COST OF ILLNESS PASIEN KANKER PARU-PARU RAWAT INAP DI RUMAH SAKIT DI BANDUNG.
JCPS (Journal of Current Pharmaceutical Sciences), [S.l.], v. 7, n. 2, p. 709-716, apr. 2024.
ISSN 2598-2095.
Available at: <https://journal.umbjm.ac.id/index.php/jcps/article/view/1107>. Date accessed: 13 oct. 2024.
Section
Articles
